ALT
Price
$8.46
Change
-$1.07 (-11.24%)
Updated
Nov 14 closing price
132 days until earnings call
KRYS
Price
$184.22
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
108 days until earnings call
Ad is loading...

ALT vs KRYS

Header iconALT vs KRYS Comparison
Open Charts ALT vs KRYSBanner chart's image
Altimmune
Price$8.46
Change-$1.07 (-11.24%)
Volume$5.19M
CapitalizationN/A
Krystal Biotech
Price$184.22
Change-$0.00 (-0.00%)
Volume$201.97K
CapitalizationN/A
ALT vs KRYS Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ALT vs. KRYS commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Buy and KRYS is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (ALT: $8.45 vs. KRYS: $177.39)
Brand notoriety: ALT and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 185% vs. KRYS: 115%
Market capitalization -- ALT: $600.9M vs. KRYS: $5.3B
ALT [@Biotechnology] is valued at $600.9M. KRYS’s [@Biotechnology] market capitalization is $5.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $475.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 1 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 6 TA indicator(s) are bullish while KRYS’s TA Score has 5 bullish TA indicator(s).

  • ALT’s TA Score: 6 bullish, 4 bearish.
  • KRYS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ALT is a better buy in the short-term than KRYS.

Price Growth

ALT (@Biotechnology) experienced а +13.34% price change this week, while KRYS (@Biotechnology) price change was -4.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.06%. For the same industry, the average monthly price growth was +3.26%, and the average quarterly price growth was +6.14%.

Reported Earning Dates

ALT is expected to report earnings on Mar 27, 2025.

KRYS is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (-2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($5.3B) has a higher market cap than ALT($601M). KRYS YTD gains are higher at: 42.987 vs. ALT (-24.844). KRYS has higher annual earnings (EBITDA): 120M vs. ALT (-100.91M). KRYS has more cash in the bank: 560M vs. ALT (165M). ALT has less debt than KRYS: ALT (1.86M) vs KRYS (7.69M). KRYS has higher revenues than ALT: KRYS (166M) vs ALT (409K).
ALTKRYSALT / KRYS
Capitalization601M5.3B11%
EBITDA-100.91M120M-84%
Gain YTD-24.84442.987-58%
P/E RatioN/A99.66-
Revenue409K166M0%
Total Cash165M560M29%
Total Debt1.86M7.69M24%
FUNDAMENTALS RATINGS
ALT vs KRYS: Fundamental Ratings
ALT
KRYS
OUTLOOK RATING
1..100
247
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
766
SMR RATING
1..100
9658
PRICE GROWTH RATING
1..100
3545
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (84) in the Pharmaceuticals Major industry is in the same range as ALT (85) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew similarly to ALT’s over the last 12 months.

KRYS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for ALT (76) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew significantly faster than ALT’s over the last 12 months.

KRYS's SMR Rating (58) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALT (96) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew somewhat faster than ALT’s over the last 12 months.

ALT's Price Growth Rating (35) in the Miscellaneous Commercial Services industry is in the same range as KRYS (45) in the Pharmaceuticals Major industry. This means that ALT’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that KRYS’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTKRYS
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 7 days ago
76%
Declines
ODDS (%)
Bearish Trend 15 days ago
88%
Bearish Trend 1 day ago
75%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
75%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EVNT10.69N/A
N/A
AltShares Event-Driven ETF
JULZ43.42-0.20
-0.46%
Trueshares Structured Outcome July ETF
CFO71.65-0.66
-0.91%
VictoryShares US 500 Enh Vol Wtd ETF
IMCG77.34-0.93
-1.19%
iShares Morningstar Mid-Cap Growth ETF
IDNA23.81-0.66
-2.70%
iShares Genomics Immnlgy & Hlthcr ETF

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with CLDX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-3.71%
CLDX - KRYS
54%
Loosely correlated
-4.10%
BEAM - KRYS
46%
Loosely correlated
-4.33%
ZLDPF - KRYS
45%
Loosely correlated
-0.86%
RXRX - KRYS
44%
Loosely correlated
-5.60%
VCYT - KRYS
44%
Loosely correlated
-6.30%
More